Results 171 to 180 of about 9,340 (184)

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

New England Journal of Medicine, 2017
Michael E Wechsler, Praveen Akuthota, David Jayne   +2 more
exaly  

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

New England Journal of Medicine, 2017
Ian D Pavord, Gerard J Criner, Jean-Benoit Martinot   +2 more
exaly  

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

New England Journal of Medicine, 2009
Pranabashis Haldar, Christopher E Brightling, Sumit Gupta   +2 more
exaly  

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

New England Journal of Medicine, 2008
Marc E Rothenberg, Amy D Klion, Jean-Emmanuel Kahn   +2 more
exaly  

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab

American Journal of Respiratory and Critical Care Medicine, 2018
Manali Mukherjee, Melanie Kjarsgaard, Nicola LaVigne   +2 more
exaly  

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

Lancet Respiratory Medicine,the, 2016
Steven W Yancey, Oliver N Keene, Eugene R Bleecker   +2 more
exaly  

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

New England Journal of Medicine, 2009
Parameswaran Nair, Melanie Kjarsgaard, Emilio Pizzichini   +2 more
exaly  

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

New England Journal of Medicine, 2014
Sally E Wenzel, Oliver N Keene, Steven W Yancey   +2 more
exaly  

Mepolizumab

Drugs of the Future, 2007
null Revill, P., null Mealy, N.
openaire   +1 more source

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2019
Kenneth R Chapman, Frank C Albers, Xavier Muñoz Gall   +2 more
exaly